RxDoctor Payments Data

Matthew Greene, OD

Optometrist · Americus, GANPI 1457616898

Payments from drug & device makers

$1,398in general payments, 2019–2025

Across 56 payments — averaging $24.96 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$724
  • Tarsus Pharmaceuticals, Inc.$156
  • Alcon$154
  • Dompe US, Inc.$100
  • Bausch & Lomb Americas Inc.$66
  • Glaukos Corporation$48
  • plus $151 from 6 others

What the payments were for

  • Food & beverage$1,38099%
  • Education$181%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,398 in reported general payments places this provider in the 60th percentile of 1,285 optometrist providers in Georgia.

See all optometrist providers in Georgia

Medicare billing

Part B allowed, 2024
$46,053
Medicare patients
273
Services billed
551

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
LumiganBimatoprost244$94,958
CombiganBrimonidine Tartrate/Timolol115$26,513
Brimonidine Tartrate-TimololBrimonidine Tartrate/Timolol94$8,412
Alphagan PBrimonidine Tartrate26$7,018
RocklatanNetarsudil Mesylat/Latanoprost14$5,225
Latanoprost465$3,886
Fluorometholone60$3,801
Brimonidine Tartrate58$1,390
Timolol Maleate110$1,089
Prednisolone Acetate19$695
Neomycin-Polymyxin-DexamethNeomycin/Polymyxin B/Dexametha48$549
Ketorolac Tromethamine11$529
Dorzolamide-TimololDorzolamide Hcl/Timolol Maleat26$430
Dorzolamide Hcl17$310
Ofloxacin17$171

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieLumigan, Combigan, Alphagan P$724$128,489385 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 60th percentile of 1,285 optometrist providers in Georgia.

Other optometrist in Americus

See the full list for Georgia

Where these figures come from

Is this you, or does something look wrong? →